Cat. No. | Product name | CAS No. |
DC12391 |
BL-AD008
Featured
BL-AD008 (BL-AD 008) is a novel small molecule, dual-target activator targeting AMPK/ZIPK; demonstrates remarkable anti-proliferative activities toward cervical cancer cells and could induce apoptosis by death-receptor and mitochondrial pathways; also sho |
|
DC4196 |
Bleomycin Sulfate
Featured
Bleomycin sulfate (Blenoxane) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells. |
9041-93-4 |
DC20801 |
BLT-1
Featured
BLT-1 is an irreversible Scavenger receptor class B member I (SR-BI) inhibitor that blocks SR-BI-mediated selective lipid uptake and bidirectional cholesterol flux with an IC50 of 50 nM; significantly inhibits baicalin-induced cholesterol efflux in THP-1 macrophages. |
321673-30-7 |
DC10530 |
BLU-285 (Avapritinib)
Featured
BLU-285 is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. |
1703793-34-3 |
DC10092 |
BLU554(Fisogatinib)
Featured
BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor. |
1707289-21-1 |
DC11479 |
BLU-667 (Pralsetinib)
Featured
BLU-667 (Pralsetinib) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. |
2097132-94-8 |
DC11152 |
BLU-782
Featured
BLU-782 (BLU782) is a novel potent, selective inhibitor of Activin receptor-like kinase (ALK2) mutant R206H with binding IC50 of <10 Nm. |
2141955-96-4 |
DC8280 |
BLU-9931
Featured
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM). |
1538604-68-0 |
DC8103 |
BLZ-945
Featured
BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM; >3200-fold higher than its affinity for other kinases. |
953769-46-5 |
DC9853 |
BM212
Featured
BM-212 is a potent antimycobacterial agent and MmpL3 inhibitor. |
146204-42-4 |
DC7959 |
BMH-21
Featured
BMH-21 is a small molecule DNA intercalator that binds ribosomal DNA and inhibits RNA polymerase I transcription; does not cause phosphorylation of H2AX. |
896705-16-1 |
DC7840 |
BML-190
Featured
BML-190 is an indomethacin morpholinylamide which functions as a selective inverse agonist of the human cannabinoid CB2 receptor. |
2854-32-2 |
DC8660 |
BML-210(CAY10433)
Featured
BML-210 is the novel HDAC inhibitor, and its mechanism of action has not been characterized. |
537034-17-6 |
DC8270 |
BML-277
Featured
BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM. |
516480-79-8 |
DC9951 |
AMBMP
Featured
AMBMP hydrochloride is a Wnt canonical signaling activator. Also inhibits tubulin polymerization. Suppresses TLR2/4/5-induced inflammatory response in human monocytes. Inhibits cell proliferation and induces cell cycle arrest in MDA-MB-231 breast cancer c |
853220-52-7 |
DC8453 |
Talazoparib(BMN-673)tosylate
Featured
Talazoparib, also known as BMN-673 and MDV-3800, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity (PARP1 IC50 = 0.57 nmol/L). Talazoparib acts as an inhibitor of poly ADP ribose polymerase(PARP) which aids in single strand DNA repair. Cells that have BRCA1/2 mutations are susceptible to the cytotoxic effects of PARP inhibitors because of an accumulation of DNA damage. Talazoparib is theorized to have a higher potency than olaparib due to the additional mechanism of action called PARP trapping. PARP trapping is the mechanism of action where the PARP molecule is trapped on the DNA, which interferes with the cells ability to replicate. Talazoparib is found to be ~100 fold more efficient in PARP trapping than olaparib. |
1373431-65-2 |
DC2008 |
Talazoparib(BMN-673)
Featured
BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM. |
1207456-01-6 |
DC23833 |
SB 4 (Eticovo)
Featured
BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes. |
100874-08-6 |
DC22988 |
BMS-189453
Featured
BMS-189453 (BMS189453, BMS453) is a synthetic retinoid that acts as an agonist of RARβ and an antagonist of RARα and RARγ. |
166977-43-1 |
DC8513 |
BMS-3
Featured
BMS-3 is a potent inhibitor of the LIM kinase. It has IC50's of 5nM and 6 nM for LIMK1 and LIMK2 respectively. |
1338247-30-5 |
DC7375 |
BMS-303141
Featured
BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor with IC50 value of 0.13 uM (human recombinant ACL). |
943962-47-8 |
DC8457 |
BMS-309403
Featured
BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E. |
300657-03-8 |